STOCK TITAN

Calliditas Therapeutics Ab - CALT STOCK NEWS

Welcome to our dedicated page for Calliditas Therapeutics Ab news (Ticker: CALT), a resource for investors and traders seeking the latest updates and insights on Calliditas Therapeutics Ab stock.

Calliditas Therapeutics AB (CALT) is a clinical-stage biopharmaceutical leader developing innovative therapies for rare renal and hepatic diseases. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships shaping the future of orphan disease treatment.

Access timely announcements covering critical developments in IgA nephropathy research, NOX enzyme inhibitor advancements, and global commercialization efforts. Our curated collection includes press releases on Phase 3 trial results, FDA/EMA regulatory reviews, and licensing agreements with international partners.

Key focus areas include updates on lead product Nefecon® in IgAN therapy, setanaxib trials for fibrotic diseases, and market expansion strategies. Bookmark this page to stay informed about Calliditas' progress in addressing unmet medical needs through targeted molecular therapies.

News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none
-
Rhea-AI Summary

Calliditas Therapeutics will host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021, featuring presentations from the management team and key opinion leaders. The event will cover an overview of the company's clinical development, including the successful topline data from the Phase 3 study, regulatory updates on Nefecon, and US commercialization plans. The program will run from 1:00 p.m. to 5:00 p.m. CET and will be accessible via webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
conferences
-
Rhea-AI Summary

Calliditas Therapeutics has announced the composition of its nomination committee for the upcoming 2021 Annual General Meeting (AGM). The committee includes Patrick Sobocki, Spike Loy, Karl Tobieson, and Elmar Schnee as chairman. They are responsible for proposing candidates for the board of directors and auditors, as well as determining fees. Shareholders can submit proposals to the committee until April 5, 2021, ahead of the AGM scheduled for May 27, 2021. Calliditas is focused on developing treatments for orphan diseases, particularly IgA nephropathy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
Rhea-AI Summary

Calliditas Therapeutics AB has announced the composition of its nomination committee for the 2021 Annual General Meeting (AGM). The committee includes Patrick Sobocki, Spike Loy, Karl Tobieson, and Elmar Schnee as chairman. Their responsibilities will involve preparing proposals for the elections of board members, auditors, and fee determinations ahead of the AGM scheduled for May 27, 2021. Shareholders can submit proposals to the committee until April 5, 2021. Calliditas is focused on developing treatments for orphan diseases, including its lead product candidate, Nefecon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
none
-
News
Rhea-AI Summary

On November 12, 2020, Calliditas announced the acquisition of a 62.7% stake in Genkyotex for €19.8 million, aimed at enhancing its portfolio in inflammatory diseases. The company reported positive topline results from its Phase 3 NefIgArd trial, confirming previous Phase 2b results for IgA nephropathy treatments. For Q3 2020, Calliditas reported an operating loss of SEK 104.9 million, with no recognized sales and a cash balance of SEK 1,396.9 million. The company plans to submit regulatory filings for accelerated approval in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
-
Rhea-AI Summary

Calliditas Therapeutics will release its Q3 2020 business update on November 12, 2020, at 07:00 am CET. A telephone conference with a presentation of the results will be held at 2:30 pm CET, hosted by CEO Renée Aguiar-Lucander and CFO Fredrik Johansson. The presentation will be accessible on the company's website and via audio cast. Dial-in numbers are provided for participation. Calliditas, focused on orphan indications, is advancing its lead product Nefecon for IgA nephropathy and is listed under ticker CALT.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
conferences
Rhea-AI Summary

On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, examining Nefecon® in patients with primary IgA nephropathy (IgAN). The results suggest potential efficacy in treating this autoimmune renal disease, which currently lacks approved therapies. A telephone conference to discuss the results will be held on November 9, 2020, at 2:30 pm CET, with participation details provided. Calliditas aims to commercialize Nefecon in the U.S. if approved, positioning itself strongly in the orphan drug market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.88%
Tags
conferences clinical trial
-
Rhea-AI Summary

Calliditas Therapeutics announced positive topline results from Part A of the Phase 3 NefIgArd clinical trial for Nefecon, showing a statistically significant reduction in urine protein creatinine ratio (UPCR) after 9 months compared to placebo. The trial also indicated a 7% beneficial effect on estimated glomerular filtration rate (eGFR). Nefecon was well-tolerated, and Calliditas plans to seek FDA approval in Q1 2021 and EMA approval in H1 2021 for commercialization. The trial followed 199 patients diagnosed with primary IgA nephropathy, affirming the drug's efficacy in this indication.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.88%
Tags
-
Rhea-AI Summary

Calliditas Therapeutics has successfully closed an acquisition of 62.7% of Genkyotex, valued at €19.8M, at €2.73 per share. This acquisition received foreign investment clearance from the French government. Following this, Calliditas plans to conduct a simplified mandatory cash tender offer for the remaining shares at €2.80 each, with potential additional payouts linked to regulatory approvals of Genkyotex's lead asset, setanaxib. The total acquisition cost for 100% ownership is projected at approximately €31.7M, plus contingent rights up to €55M based on future approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
Rhea-AI Summary

Calliditas Therapeutics announced presentations for its lead product Nefecon at the ASN Kidney Week 2020 conference from October 19-25. Key sessions include a poster by Professor Jonathan Barratt detailing the NefIgArd trial design, focused on patients with IgA Nephropathy at risk of End Stage Renal Disease. Additionally, Dr. Karen Molyneux will present Nefecon's impact on biomarkers in patients with the same condition. Nefecon, an investigational drug for IgAN, aims to fulfill a significant unmet medical need as there are currently no approved treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
Calliditas Therapeutics Ab

Nasdaq:CALT

CALT Rankings

CALT Stock Data

1.09B
27.02M
3.81%
0.32%
0.01%
Biotechnology
Healthcare
Link
Sweden
Stockholm